Combination immunotherapy with nivolumab and ipilimumab, another immune checkpoint inhibitor blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has been shown to be superior to monotherapies in treating some solid tumors including melanoma. This evidence concerns the gene CTLA4 and melanoma.